DECHLORO ETHYLCLOPROSTENOLAMIDE.

Given its potent pharmacological activity, Dechloro Ethylcloprostenolamide is effective at remarkably low concentrations. This characteristic renders it susceptible to 'dusting,' where minimal amounts are included in formulations to allow for ingredient listing, potentially below levels that would confer full clinical benefits or align with comprehensive regulatory scrutiny regarding efficacy and safety.

The Cosmetic Ingredient Review (CIR) prepared an assessment for its synonym, Ethyl Tafluprostamide, concluding a negligible risk of physiological effect on eyelid skin or the eye at certain concentrations, though their overall safety conclusion was 'insufficient data.' In contrast, the EU Scientific Committee on Consumer Safety (SCCS) expressed significant concerns regarding its potent pharmacological activity and intended use near the eye, advising against or prohibiting its use in eyelash growth-promoting cosmetics. The FDA classifies its uses as cosmetic, not drug uses. Potential adverse effects include lid and ocular surface inflammation, changes in lid and intraocular pigment, orbital fat atrophy, dry eye, eye discomfort, various eye disorders, headache, hypertension, hypertrichosis, skin reactions, and vision disorders. Minimal initial transient irritation was observed in some clinical trial participants. It is strongly advised that pregnant and breastfeeding individuals avoid products containing this ingredient.